leo psoriasis academy 2015€¦ · no signs of psoriasis (post-inflammatory hyperpigmentation may...

LEO Psoriasis Academy 2015

Change/Insert Date & Location

via >Insert >Header & Footer

1. Check in Date & Time

2. Type under >Fixed

3. Check in Footer

4. Fill in field

5. Click Apply to All

To view drawing guides

1. Right-click outside slide and

select ’Grid and Guides...’

2. Check ’Display drawing

guides on screen’

3. Select ’OK’

Toolkit: assessments and interventions

To add pre-formatted

bullet text please use the

Increase/Decrease Indent

buttons found in the

Top-PowerPoint menu

Content covered ◦ Psoriasis skin

severity

• BSA

• PASI

• PGA

◦ Education

• Psychological

measures

• PeDeSI

• OnderHUIDS

◦ Health-related QoL

• DLQI

• FamilyPso

• Psodisk

• EQ-5D

• SF-36

◦ Adherence

• TTOP

• TTAQ/STAQ

◦ Treatment benefit

• PBI

◦ Patient support

• PsoPlus

• PsoCare

• QualityCareTM

• MyPso QualityCareTM

• Psoriasis Academy Website

◦ Psychological burden

• HADS





Top-PowerPoint menu

Body surface area (BSA)

◦ Percentage of body surface covered by psoriasis

◦ One full hand of the patient corresponds to 1% of the body surface

◦ More accurate in patients with large lesions, tendency to overestimate when small lesions are present

◦ Widely used in clinical trials; recommended for daily practice

◦ Part of official disease severity classifications

Measures the healthcare professional (HCP)’s impression of disease severity

Established Free to use Can be used for other skin diseases





Top-PowerPoint menu

Psoriasis Area and Severity Index (PASI)

◦ As different body areas may have different types of lesions, the PASI treats the four different body areas as separate units

◦ Commonly used measure in clinical trials for psoriasis treatments; recommended for daily practice


◦ Typically, the PASI score is calculated before, during and after a treatment period in order to determine how well psoriasis responds to the treatment

Measure of overall psoriasis severity, coverage, and response to

treatment over time

Validated Free to use Psoriasis specific

Fredriksson and Petterson. Dermatologica 1978;157:238–244

Online PASI calculator: http://pasi.corti.li/

http://pasi.corti.li/





Top-PowerPoint menu

Psoriasis Area and Severity Index (PASI) ◦ The body is divided into four regions. For each region, the percentage of the area of skin

involved is calculated and then assigned a score of 0 to 6

◦ Severity is measured by three different parameters (see step 2). Each parameter is assessed separately for each region and given a score of 0 to 4

STEP 2

Assessment of the

severity of lesions:

1. Erythema (redness)

2. Induration (thickness)

3. Scaling

STEP 1

Calculating BSA covered with

lesions:

1. Head and neck

2. Upper extremities

3. Trunk

4. Lower extremities

Calculations are

combined into a

single score

(PASI score):

0 (no psoriasis) –

72 (most severe

case of psoriasis)

0% = Score 0

<10% = Score 1

10–29% = Score 2

30–49% = Score 3

50–69% = Score 4

70–89% = Score 5

90–100% = Score 6

None = Score 0

Some = Score 1

Moderate = Score 2

Severe = Score 3

Maximum = Score 4





Top-PowerPoint menu One hand-sized

area corresponds to

BSA Weighted area

for PASI

Head and neck

(10% of BSA) 1% 10%

Upper extremities

(20% of BSA) 1% 5%

Trunk

(30% of BSA) 1% 3.3%

Lower extremities

(40% of BSA) 1% 2.5%

BSA and PASI – scoring body area involvement ◦ PASI assigns weightings for different body areas (column 1) therefore 1% by BSA

corresponds to a different weighted area for PASI (column 3)





Top-PowerPoint menu

Physician’s Global Assessment (PGA)

◦ 5-, 6- or 7-point ordinal rating from clear to very severe psoriasis based on assessment of average severity of erythema, infiltration, scaling and area of involvement

◦ A static PGA is a measure of disease severity at a specific point in time

◦ A dynamic PGA is used to draw a comparison with baseline disease severity but this is not recommended by regulatory agencies

◦ Static PGA widely used in clinical trials; recommended for daily practice

PGA scale ranging from 0 to 5:

• 0 = clear

• 1 = minimal

• 2 = mild

• 3 = moderate

• 4 = marked

• 5 = severe

PGA scale ranging from 0 to 6:

• 0 = clear

• 1 = almost clear

• 2 = mild

• 3 = mild to moderate

• 4 = moderate

• 5 = moderate to severe

• 6 = severe

Measures HCP’s impression of disease severity

Validated Need permission Psoriasis specific

Reich et al. Lancet 2005;366:1367–1374; Papp et al. Lancet 2008;371:1675–1684; Langley and Ellis. J Am Acad Dermatol 2004;51:563–

569; Berth-Jones et al. Br J Dermatol 2006;155:707–713





Top-PowerPoint menu

PGA scoring

Description of a PGA

0. Clear No signs of psoriasis (post-inflammatory hyperpigmentation may

be present)

1. Almost clear Intermediate between mild and clear

2. Mild Slight plaque elevation, scaling and/or erythema

3. Mild to moderate Intermediate between moderate and mild

4. Moderate Moderate plaque elevation, scaling and/or erythema

5. Moderate to severe Marked plaque elevation, scaling and/or erythema

6. Severe Very marked plaque elevation, scaling and/or erythema

Langley and Ellis. J Am Acad Dermatol 2004;51:563–569





Top-PowerPoint menu

Measuring health-related quality of life (HRQoL) in psoriasis

◦ Generic QoL measures

• Short Form of the Medical Outcomes Study Questionnaire (SF-36)

• EuroQoL (EQ-5D)

◦ Dermatology-specific QoL measures

• Dermatology Life Quality Index (DLQI)

• Skindex1

• Dermatology-Specific Quality of Life (DSQL)2

◦ Psoriasis-specific QoL measures

• Salford Psoriasis Index (SPI)3

• Psoriasis Disability Index (PDI)

- http://www.cardiff.ac.uk/dermatology/quality-of-life/psoriasis-disability-index-pdi/

• Psoriasis QoL Index (PSORIQoL)4

1.Chen et al. J Invest Dermatol 1996;107(5):707–713 2. Rajagopalan et al. Qual Life Res 1998;7(8): 723-3 3. Kirby et al. Br J Dermatol

2000;142(4):728-31 4. McKenna et al. Br J Dermatol 2003;142(2):323-31

http://www.cardiff.ac.uk/dermatology/quality-of-life/psoriasis-disability-index-pdi/

















Top-PowerPoint menu

Dermatology Life Quality Index (DLQI)

◦ The DLQI is widely used in clinical trials; recommended for daily practice


◦ A simple 10-question validated questionnaire available in 55 languages

◦ There is a children’s version of the DLQI, the Children’s Dermatology Life Quality Index (CDLQI)1 and a text and cartoon version2

Online versions available for download at: http://www.cardiff.ac.uk/dermatology/quality-of-life/

Each question is answered by a tick

box:3

• Not at all

• A little

• Very much

Each question is scored from

0 to 3 and the scores summed,

giving a range from 0 (no

impairment in life quality) to 30

(maximum impairment)

DLQI questionnaire

10 questions covering:3

• Symptoms and feelings

• Daily activities

• Leisure

• Work and school

• Personal relationships

• Treatment

All questions relate to ‘the

last week’

Benefits

Designed to enable

patients to express

issues in their lives

caused by their skin

disease, and to

improve the quality of

patient care

Health-related QoL questionnaire

Validated Free to use* Dermatology specific

*For routine clinical use by clinicians. For details see: http://www.cardiff.ac.uk/dermatology/quality-of-life/dermatology-quality-of-life-index-dlqi/dlqi-

instructions-for-use-and-scoring/

1. Lewis–Jones and Finlay. Br J Dermatol 1995;132:942–949; 2. Holme et al. Br J Dermatol 2003;148:285–290;

3. Finlay and Khan. Clin Exp Dermatol 1994;19:210–216

http://www.cardiff.ac.uk/dermatology/quality-of-life/dermatology-quality-of-life-index-dlqi/







http://www.cardiff.ac.uk/dermatology/quality-of-life/dermatology-quality-of-life-index-dlqi/dlqi-instructions-for-use-and-scoring/






























Top-PowerPoint menu

DLQI – bands

0–1 No effect on patient’s life

2–5 Small effect

6–10 Moderate effect

11–20 Very large effect

21–30 Extremely large effect

BSA >10 or PASI >10 and DLQI >10 =

moderate to severe psoriasis

Hongbo et al. J Invest Dermatol 2005;125:659–664





Top-PowerPoint menu

EQ-5D™

◦ Available in up to 169 languages

◦ Composed of a descriptive questionnaire and visual analogue scale

◦ Questionnaire is available in 3- or 5-point scale

Visual analogue scale

Graded from 0 to 100 and

has two endpoints:

• Best imaginable health

status (100)

• Worst imaginable health

status (0)

Participants are asked to

self-assess their health by

drawing a line on the scale

Descriptive questionnaire

15 questions covering:

• Mobility

• Self-care

• Usual activities

• Pain/discomfort

• Anxiety/depression

Each question is graded

from ‘no problem’ to

‘extreme problem’

Standardised health outcome questionnaire

Validated Need permission Generic





Top-PowerPoint menu

Short form of the Medical Outcomes Study questionnaire (SF-36)

◦ The SF-36 was developed from the Medical Outcomes Study (MOS)

◦ Available in English and Arabic

◦ Widely used in clinical trials

◦ Questions from relevant sections can be used to guide consultations

Each question is answered

by a tick box:

• Answers in each section

are weighted, summed

and transformed into an

overall score between

0 and 100

• The lower the score, the

more disability

• Scores are calculated

using special software

Descriptive questionnaire

36 questions covering

eight sections:

• Vitality

• Physical functioning

• Bodily pain

• General health perceptions

• Physical role functioning

• Emotional role functioning

• Social role functioning

• Mental health

Standardised health outcome questionnaire

Validated Free to use* Generic

*No written permission required. For terms and conditions: https://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html

https://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html

https://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html





Top-PowerPoint menu

FamilyPso

◦ The questionnaire consists of 15 items, subdivided into the following five sub-categories:

• Social life

• Emotional life

• Household

• Partnership

• Environmental reactions

A self-assessment scale developed to assess QoL for family members

and partners of patients with psoriasis

Published Free to use Psoriasis specific

Zschocke et al. Arch Dermatol Res 2014;306:287–297





Top-PowerPoint menu

Systematic

literature research

Identification of

adherence factors

for topical therapy

Input from

patient experts (EuroPso)

Input from psoriasis Elke de Jong, Nijmegen, NL

experts Lluís Puig, Barcelona, ES

Hervé Bachelez, Paris, FR

Richard Warren, Manchester, UK

Paolo Gisondi, Verona, IT

Ulrich Mrowietz, Kiel, DE

Kristian Reich, Hamburg, DE

Topical Treatment Optimization Program (TTOP)

◦ Addressing ‘patient characteristics’ that influence adherence

• For example, treatment

expectation, forgetfulness,

misunderstanding of treatment

instructions, fear of possible side

effects, etc

• Improving ‘patient

communication’

─ For example, holistic approach, patients are

asked to give their feedback on how they

find their treatment, etc

• Improving ‘HCP communication’

─ For example, increased amount of

information given to the patients in a time-

efficient way, through the use of checklists,

etc, to keep the patient consultation

streamlined

Development of the

TTOP

Adherence-enhancing intervention aimed at

improving the information provided to patients


Reich et al. Arch Dermatol Res 2014;306:667–776





Top-PowerPoint menu

TTOP: a management and communication tool ◦ Standardised checklist for HCPs including communication tool

◦ Standardised checklist for nurses including communication tool

◦ Written patient information material on disease, treatment and FAQs

◦ Helpdesk function for patients in between visits: email and cell phone

◦ Treatment reminders

◦ Checklists modified from published versions for use in daily clinical practice

• Available through the Psoriasis Academy (see appendix)

Reich et al. Arch Dermatol Res 2014;306:667–776





Top-PowerPoint menu

Treatment Adherence (TTAQ/STAQ)

◦ Questions assess three main adherence-driving aspects:

• Physician–patient relation

• Therapy benefit

• Treatment satisfaction

◦ The original questionnaire consists of 59 items, amongst them several items to assess properties of topical therapies

◦ The questionnaire has been developed further to a 38-item inventory to assess the three subscales, regardless of whether the patient is treated with a topical or a systemic drug

◦ Questions from relevant sections can be used to guide consultations

Zschocke et al. Arch Dermatol Res 2014;306:287–297

A self-assessment scale developed to detect the most

relevant adherence driving aspects

Published,

validation ongoing (expected in November

2015)

Free to use

(clinicians)/need

permission

(industry)

Psoriasis specific





Top-PowerPoint menu

Patient Benefit Index (PBI)

◦ Assessment consists of two steps:

◦ Patient defines their treatment needs before treatment from a preformed list

◦ Patient rates the benefits achieved after treatment

◦ The global score is the average of benefits achieved after treatment, weighted by the individual importance of treatment needs

Questionnaire designed to assess patient-relevant treatment benefits

in dermatology

Validated Free to use Dermatology specific

Feuerhahn et al. Arch Dermatol Res 2012;304:433–441;

Radtke et al. Eur J Dermatol 2013:23:212–217





Top-PowerPoint menu

Hospital Anxiety and Depression Scale (HADS)

◦ The anxiety and depressive subscales are valid measures of severity of the emotional disorder

◦ All the ‘A’ scores (measure of anxiety) and all the ‘D’ scores (measures of depression) are added together independently

◦ The total score of each defines the level of anxiety/depression:

0–7 Normal

8–10 Borderline abnormal

11–21 Abnormal

Online version available for download: http://opencourses.emu.edu.tr/pluginfile.php/8619/mod_resource/content/1/HADS.pdf

A self-assessment scale developed to detect states of depression and anxiety in hospital medical

outpatient clinics

Validated Free to use General

Zigmond and Snaith. Acta Psychiatr Scand 1983;67:361–370

http://opencourses.emu.edu.tr/pluginfile.php/8619/mod_resource/content/1/HADS.pdf







Top-PowerPoint menu

Psychological measures

◦ A two-stage qualitative and quantitative study was conducted to identify key statements associated with the psychological impact of psoriasis

◦ The authors concluded that specific questions relating to isolation, social stigma, impact of psoriasis on activities and feelings of hopelessness should be included in consultations

◦ Patients should also be helped to develop realistic expectations of newly prescribed treatments, followed by constructive discussion of the reasons for non-adherence over time

◦ This approach has the potential to maximise the chances of optimal adherence and may identify patients who might benefit from approaches to optimise treatment effectiveness, through adherence enhancement and related support of patient self-management and coping

Link to study

Identification of key

statements

associated with a

strong burden of

psoriasis on patients’

lives based on

isolation, social

stigma, visible

symptoms, impact

on activities and

feelings of

hopelessness

QUALITATIVE

COMPONENT

Identified issues

faced by patients,

their current

practices and beliefs

relating to psoriasis

through the

completion of an

online survey

Benefits

Questioning using the

statements most

associated with

psychosocial impact

and non-adherence

could help identify

patients with additional

support needs, and

assist in overcoming

adherence issues

Key statements used during consultation could help identify patients with support needs


QUANTITATIVE

COMPONENT

Determined the

applicability of the

issues in the wider

population

Bewley et al. J Eur Acad Dermatol Venereol 2014;28:763–770

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229026/





Top-PowerPoint menu

The Person-Centered Dermatology Self-Care Index (PeDeSI)

◦ 10-item questionnaire developed (PeDeSI)

◦ The score should be agreed with the patient

◦ Knowledge and professional judgement are required when agreeing a score

◦ Every item must be scored

Questionnaire designed to make systematic and accurate assessment of the education and

support needs of adults with long-term skin conditions

Validated Free to use Psoriasis specific

Each score reflects the

combination of the

person’s knowledge,

skill and confidence in a

particular ability

Scores are summed to give a total score

out of 30. Patients with low scores (0–10)

require intensive education and support

to develop knowledge, ability and

confidence; patients with higher scores

≥21 require minimal support, while those

patients scoring 30 are deemed to have

sufficient knowledge, ability and

confidence to manage on their own

Patients and clinicians complete the

questionnaire and action plan together

Each question is answered and scored as

follows:

0 = no ability

1 = some ability

2 = sufficient ability

3 = full ability

Cowdell et al. J Arch Dermatol 2012;148:1251–1255





Top-PowerPoint menu

The Person-Centered Dermatology Self-Care Index (PeDeSI)

Benefits

• The tool enables clinicians to assess and

evaluate the learning needs of patients such that

they are able to engage in self-management of

their condition (with support); effectively

supporting treatment adherence

• Inclusion of an action plan in which realistic

patient-determined goals are agreed on,

documented and reviewed in true partnership

interactive style ensures that the needs of

patients are most likely to be achieved

• The index provides a basis for evaluating over

time the effectiveness of measures to support

self-management: a crucial factor in treatment

efficacy

Cowdell et al. J Arch Dermatol 2012;148:1251–1255





Top-PowerPoint menu

PeDeSI questions

◦ Do you have an understanding of your skin condition?

◦ Do you know what things make your skin condition better or worse?

◦ What is this treatment used for?

◦ Are you aware of how long initial treatment will take to be effective?

◦ Do you know what the common side effects for your treatment(s) are?

◦ Do you know how much should be applied each time and when?

◦ Can you apply the treatment(s) to the affected areas? (Demonstrate)

◦ Do you know how and when to adapt treatment or seek help if condition gets worse?

◦ Do you know how to obtain a repeat prescription?

◦ Do you feel confident to use your treatment(s) at home yourself?





Top-PowerPoint menu

OnderHUIDS – patient education programme

◦ OnderHUIDS is a multidisciplinary educational programme for patients, 18 years or older, with chronic skin diseases1

◦ The 12-week intervention encompasses cognitive education on skin and general health issues, and stress-reducing techniques1

◦ Its design is based on the premise that lifestyle factors can influence the course of skin diseases, especially in psoriasis

Multidisciplinary educational programme for patients with chronic skin diseases

Published Need permission Dermatology specific

Benefits

• In a randomised controlled trial, the

OnderHUIDS patient education

programme was found to contribute

to improved disease severity and

quality of life at 3 months in patients

with psoriasis2

• This improvement continued for at

least 6 months, ie 3 months after the

intervention, and was not related to

major changes in medical therapy or

influence of seasonal variation2

1. Lambert et al. Arch Dermatol Res 2011;303:57–63;

2. Bostoen et al. Br J Dermatol 2012;167:1025–1031





Top-PowerPoint menu

OnderHUIDS – patient education programme

Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9 Week 10 Week 11 Week 12

→ 2- or 3-hour sessions twice a week

An interdisciplinary team of trainers is involved:

• Dermatologist

• Dermatologic nurse

• Pharmacist

• Psychiatrist

• Psychologist

• Dietician

• Philosopher

• Training expert

• Sports, mindfulness and yoga teacher

Specific

information on

skin diseases

and skin care

Four sessions

Total duration:

7 hours

Stress-reduction

techniques: physical

training, yoga,

mindfulness-based

stress reduction

29 sessions

Total duration:

41 hours

Information sessions on lifestyle and

psycho-dermatology: diet, responsible

physical training, sleep hygiene, smoking

cessation, substance abuse, psycho-

dermatology, practical philosophy

Nine sessions

Total duration:

11 hours

Feedback:

individual and

in group

One session

Total duration:

1 hour 15 mins





Top-PowerPoint menu

Psodisk

Smartphone app available for download:

https://play.google.com/store/apps/details?id=com.abbvie.psodisk

Development of a

preliminary Italian

questionnaire to

assess global

impact of psoriasis

on patients

Input from panel of experts

(Delphi survey)

Input from focus

groups

Development of a

10-item visual

instrument that uses a

10-point visual

analogue scale to

graphically represent

the burden of psoriasis

on a disc as a polygon

10-item visual instrument aimed at measuring the

burden of psoriasis on patients

Published Need

permission

Psoriasis

specific

Benefits

• Ability to visualise the course of a patient’s

psoriasis by looking at the modification of

the polygon’s area

• Used during clinical practice and is filled

out by the patient with the dermatologist

• This may improve communication

between patient and dermatologist and

have important positive consequences

on adherence to treatment

Sampogna et al. J Eur Acad Dermatol Venereol 2014;29:725–731








Top-PowerPoint menu

QualityCareTM

◦ People with psoriasis can create their own unique profiles in order to receive support tailored to their specific concerns, preferences and demographic information

◦ Provides free, confidential access to support across multiple channels, including website, nurse calls, text messages and emails

◦ Based on patient needs: more than 4000 people with psoriasis from multiple countries were consulted

Online support platform that provides a variety of resources to patients with psoriasis

In use* Free to use Psoriasis specific

Understanding psoriasis Living with psoriasis

Managing treatment

Handling symptoms

Blogger universe** Nurse call centre**

* Available in a growing number of countries, for more information ask your LEO representative

**Available in selected countries





Top-PowerPoint menu

MyPso QualityCareTM – psoriasis self-track

◦ Two objectives: improve patient adherence and consultation with dermatologist

App that allows patients to track the progression of their psoriasis

Available Need permission Psoriasis specific

Benefit:

• Initiate consultation; understand individual needs

• Drive consultation based on facts, not feelings

• Optimise time

Benefit:

• Get progress based on facts – control and empowerment

• App feedback based on individual report – motivation

• Report based on facts, not feelings – better consultation

Patient requirements: • Easy and visual • Empowerment

HCP requirement: • Easy and fast to read • Supportive vs substitutive • Time saving





Top-PowerPoint menu

User experience Menu Bar allows choice of three tracking options and access to results

Res

ult

s

Graphic: • Symptoms • Triggers • Adherence

barriers

Comparison: • Symptoms and

severity • Triggers

Photo library: • Symptoms

and severity • Triggers

QualityCare™: • Platform where

patients can get more information

Tra

ckin

g

Symptoms: • Severity • Adherence • Barriers

Triggers: • Potential

triggers

Photos: • Pictures per

body area





Top-PowerPoint menu

App summary Overview of functionalities

TRACK SYMPTOMS • Personalised symptom • Severity symptom • Adherence track • Adherence barrier

TRACK TRIGGERS • Choose from

10 triggers

TRACK PHOTOS • Personalised body gender • Choose body area • Collect pictures

ME GRAPHIC • Graphic • Symptom selector • Time graphic selector • Timely trigger and barrier • Landscape complete view

COMPARE • % of people like me • Rate of people like me • Also what’s not tracked

PHOTO LIBRARY • Body area selection • Date selection • Video effect

QUALITYCARETM

• MyPso integrated with patient support programme QualityCareTM

SETTINGS • Treatment reminder • Track reminder • Adjust my selections

SHARE • PDF report by email • Recommend the app

http://www.google.dk/url?sa=i&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&uact=8&ved=0CAcQjRw&url=http://www.flaticon.com/free-icon/users-group_32441&ei=P6NjVOS6KtGw7AampYDADQ&psig=AFQjCNHfl6d4-zvheaVg_80YloJBdhA3gw&ust=1415902301684060





Top-PowerPoint menu

Psoriasis Academy website

◦ A non-promotional web platform to engage with participants of the Academy

◦ http://psoriasisacademy.leo-pharma.com/

◦ Initial offerings:

• Discussion forum

• Access to tools and materials from the Academy

• Newsletter

http://psoriasisacademy.leo-pharma.com/




Change/Insert Date & Location

via >Insert >Header & Footer

1. Check in Date & Time

2. Type under >Fixed

3. Check in Footer

4. Fill in field

5. Click Apply to All

To view drawing guides

1. Right-click outside slide and

select ’Grid and Guides...’

2. Check ’Display drawing

guides on screen’

3. Select ’OK’

Patient support programmes





Top-PowerPoint menu

Overview of section

◦ This section is a list of region-specific support programmes and associations





Top-PowerPoint menu

European and international support

◦ International Federation of Psoriasis Associations – www.ifpa-pso.org

• A non-profit federation made up of psoriasis associations from around the world

• Aims to secure universal access to treatment, raise awareness and understanding of psoriasis, and change treatment paradigms

• Provides links to national patients’ associations

◦ EUROPSO – www.europso.eu

• A non-profit federation for psoriasis patients’ associations in Europe

• Advocates in favour of equal treatment, opportunity and information for all psoriasis patients across Europe

• Supports the emergence and establishment of psoriasis patients’ associations in emerging

European countries

• Provides links to national European patients’ associations

http://www.ifpa-pso.org/



http://www.europso.eu/





Top-PowerPoint menu

Europe Country Patient resources Website

Austria QC

Pso Austria

Hautinfo

ForumPsoriasis

www.psoriasis-hilfe.at

www.hautinfo.at

www.forumpsoriasis.at

Germany QC PsoAktuell

Deutscher Psoriasis Bund

http://www.psoaktuell.com/selbsthilfe.htm

http://www.psoriasis-bund.de/

France QC France Psoriasis http://francepsoriasis.org/

Italy QC ADIPSO www.adipso.org

Spain Acción Psoriasis http://www.accionpsoriasis.org/

Netherlands QC Psoriasis Vereniging Nederland

Psoriasis Federatie Nederland

www.psoriasisvereniging.nl

www.psoriasis-fn.nl

Portugal QC Pso Portugal www.psoportugal.pt

United Kingdom QC

Psoriasis Association

Skin Conditions Campaign Scotland

PSALV

British Skin Foundation

Skin Care Cymru

Irish Skin Foundation

https://www.psoriasis-association.org.uk/

http://www.skinconditionscampaignscotland.org/

http://www.psoriasisscotland.org.uk

http://www.britishskinfoundation.org.uk/

http://www.skincarecymru.org/

http://irishskinfoundation.ie/

Switzerland QC Schweizerische Psoriasis und Vitiligo Gesellschaft www.spvg.ch

Belgium QC Pso Contact

Psoriasis Liga

Groupe d’Aide à la Recherche et à l’Information sur le

Psoriasis

www.psoriasis-contact.be

www.psoriasis-vl.be

http://www.gipso.info/

Russia QC Society of Patients with Psoriasis http://www.psoriasregion.ru

QC indicates the QualityCareTM patient support programme is available. For more information on QualityCareTM refer to Toolkit

http://www.psoriasis-hilfe.at/



http://www.hautinfo.at/

http://www.forumpsoriasis.at/

http://www.psoaktuell.com/selbsthilfe.htm




http://francepsoriasis.org/

http://www.adipso.org/

http://www.accionpsoriasis.org/

http://www.psoriasisvereniging.nl/

http://www.psoriasis-fn.nl/



http://www.psoportugal.pt/




http://www.skinconditionscampaignscotland.org/

http://www.psoriasisscotland.org.uk/

http://www.britishskinfoundation.org.uk/

http://www.skincarecymru.org/

http://irishskinfoundation.ie/

http://www.spvg.ch/

http://www.psoriasis-contact.be/



http://www.psoriasis-vl.be/



http://www.gipso.info/

http://www.psoriasregion.ru/





Top-PowerPoint menu

Asia

QC indicates the QualityCareTM patient support programme is available. For more information on QualityCareTM refer to Toolkit

Country Patient resources Website

Korea QC

1) Korea Psoriasis Association

- One of the biggest psoriasis patient organizations in

Korea

- Number of members: 11,051

2) Noonsaram

- Another active psoriasis patient organization.

However, their website is currently under construction

and not available.

http://www.gunsun.org/

Japan Japan Psoriasis Association http://jpa1029.com/index.html

Vietnam PsorViet www.psorviet.org

www.vaynen.org

Indonesia Indonesia Psoriasis Care Foundation

Yayasan Peduli Psoriasis Indonesia

http://www.psoriasisindonesia.org/2012/

Malaysia 1) Psoriasis Association of Malaysia (PAM) - National

Level

2) Psoriasis Association ofJohor (PAJ) - State Level

https://psoriasismalaysia.wordpress.com/

https://www.facebook.com/psoriasismalaysia

https://www.facebook.com/PersatuanPsoriasisJoh

or/photos_stream

Taiwan Psoriasis Association Taiwan http://www.psoat.org.tw/

Philippines PsorPhil http://www.psorphil.org/

Singapore Psoriasis Association of Singapore http://psoriasis.org.sg/

China QC No patient organizations

Sri Lanka No Psoriasis patient organization

Thailand No Psoriasis patient organization

http://www.gunsun.org/

http://jpa1029.com/index.html

http://www.psorviet.org/

http://www.vaynen.org/

http://www.psoriasisindonesia.org/2012/

https://psoriasismalaysia.wordpress.com/

https://www.facebook.com/psoriasismalaysia

https://www.facebook.com/PersatuanPsoriasisJohor/photos_stream

https://www.facebook.com/PersatuanPsoriasisJohor/photos_stream

http://www.psoat.org.tw/

http://www.psorphil.org/

http://psoriasis.org.sg/

leo psoriasis academy 2015€¦ · no signs of psoriasis (post-inflammatory hyperpigmentation may...

Documents